Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Quest Diagnostics, Genalyte

Premium

Quest Diagnostics this week released two tests for the diagnosis of rheumatoid arthritis based on the 14-3-3eta protein.

One test consists 14-3-3eta protein alone, while the other includes this protein along with established RA markers cyclic citrullinated peptide antibodies and rheumatoid factor. The tests, are intended for the diagnosis of RA, and early diagnosis of the disease in particular, the company said.

Quest licensed US rights to the 14-3-3eta protein from Canadian biotech firm Augurex (see related story this issue).


Genalyte this week released its MT-ADA anti-drug antibody immunogenicity assay for drug development.

The assay is intended for detecting unwanted immune responses to drugs by measuring the presence of anti-drug antibodies. The test allows for simultaneous detection of eight antibody classes and can be used for both mouse and human samples, the company said.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.